| 盐酸吡格列酮对早期2型糖尿病肾病患者hs—CRP及PAI-1水平的影响 |
| |
| 引用本文： | 康剑云,刘宝生.盐酸吡格列酮对早期2型糖尿病肾病患者hs—CRP及PAI-1水平的影响[J].中国药师,2011,14(5):695-697. |
| |
| 作者姓名： | 康剑云 刘宝生 |
| |
| 作者单位： | 河北北方学院附属第二医院内一科,河北张家口,075100 |
| |
| 摘 要： | 目的：观察盐酸吡格列酮对早期耱尿病肾病患者超敏C反应蛋白（hs-CRP）及血浆纤溶酶原激活物抑制物-1（PAI-1）水平的影响。方法：选取早期糖尿病肾病患者80例，随机分为治疗组和对照组，两组患者在良好控制血压、血糖的基础上．对照组口服安慰剂（谷维素），治疗组加用盐酸吡格列酮15mg，po，qd，疗程6个月，观察治疗前后空腹血糖（FBG）、糖化血红蛋白（HbA1c）、胆固醇（TC）、三酰甘油（TG）、空腹胰岛素（FNS）、hs—CRP、PAI-1、尿微量白蛋白排泄率（UAER）等指标的变化情况。结果：盐酸吡格列酮治疗6个月后患者的FBG、HbA1c、TC、TG，hs—CRP、PAI-1、UAER、FNS、胰岛素抵抗指数（IRI）比治疗前明显下降（P〈0．05或0．01），且明显低于对照组（P〈0．05或0．01）。结论：早期2型糖尿病肾病患者应用盐酸吡格列酮治疗，可以改善胰岛素抵抗及糖脂代谢，还可以降低尿微量白蛋白、hs—CRP、PAI—1水平，对延缓早期2型糖尿病肾病的发展有益．
|
| 关 键 词： | 盐酸吡格列酮 早期2型糖尿病肾病 超敏C反应蛋白 血浆纤溶酶原激活物抑制物-1 |
Effects of Piogliazone Hydrochloride on the Serum Levels of hs-CRP and PAI-1 in Patients with Early Type 2 Diabetic Renopathy |
| |
| Kang Jianyun,Liu Baosheng.Effects of Piogliazone Hydrochloride on the Serum Levels of hs-CRP and PAI-1 in Patients with Early Type 2 Diabetic Renopathy[J].China Pharmacist,2011,14(5):695-697. |
| |
| Authors: | Kang Jianyun Liu Baosheng |
| |
| Institution: | Kang Jianyun,Liu Baosheng(Internal Medicine,the Second Affiliated Hospital of Hebei North University,Hebei Zhangjiakou 075100,China) |
| |
| Abstract: | Objective:To observe the effects of pioglitazone hydrochloride on the serum levels of high sensitivity C-reactive protein (hs-CRP)and plasminogen activator inhibitor-1(PAI-1)in patients with early type 2 diabetic Tenopathy.Method:Eighty patients with early type 2 diabetic Tenopathy were recruited and divided randomly into the treatment and control group.Both groups had an excellent basal control.of blood pressure and blood sugar.The treatment group received an additional medication of pioglitazone hydrochlo... |
| |
| Keywords: | Pioglitazone hydrochloride Early type 2 diabetic renopathy High sensitivity C-reactive protein Plasminogen activator inhibitor-1 |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
